X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CADILA HEALTHCARE - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CADILA HEALTHCARE ASTRAZENECA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 122.0 33.5 364.2% View Chart
P/BV x 17.4 8.6 201.4% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
CADILA HEALTHCARE
Mar-16
ASTRAZENECA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,285454 282.8%   
Low Rs634305 208.2%   
Sales per share (Unadj.) Rs189.696.1 197.3%  
Earnings per share (Unadj.) Rs-0.214.9 -1.4%  
Cash flow per share (Unadj.) Rs3.817.8 21.6%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs68.652.3 131.3%  
Shares outstanding (eoy) m25.001,023.74 2.4%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x5.13.9 128.2%   
Avg P/E ratio x-4,712.725.5 -18,471.8%  
P/CF ratio (eoy) x249.621.3 1,172.4%  
Price / Book Value ratio x14.07.3 192.6%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m23,988388,458 6.2%   
No. of employees `0001.615.4 10.1%   
Total wages/salary Rs m1,60513,317 12.0%   
Avg. sales/employee Rs Th3,040.26,371.1 47.7%   
Avg. wages/employee Rs Th1,029.2862.4 119.3%   
Avg. net profit/employee Rs Th-3.3986.1 -0.3%   
INCOME DATA
Net Sales Rs m4,74098,376 4.8%  
Other income Rs m92941 9.8%   
Total revenues Rs m4,83299,317 4.9%   
Gross profit Rs m-13023,829 -0.5%  
Depreciation Rs m1013,022 3.3%   
Interest Rs m0486 0.0%   
Profit before tax Rs m-13921,262 -0.7%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m139-25 -555.6%   
Tax Rs m55,716 0.1%   
Profit after tax Rs m-515,226 -0.0%  
Gross profit margin %-2.724.2 -11.3%  
Effective tax rate %-3.726.9 -13.6%   
Net profit margin %-0.115.5 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,72644,376 6.1%   
Current liabilities Rs m2,43534,071 7.1%   
Net working cap to sales %6.110.5 58.7%  
Current ratio x1.11.3 86.0%  
Inventory Days Days7454 137.0%  
Debtors Days Days4162 65.4%  
Net fixed assets Rs m1,03547,896 2.2%   
Share capital Rs m501,024 4.9%   
"Free" reserves Rs m94248,746 1.9%   
Net worth Rs m1,71653,519 3.2%   
Long term debt Rs m08,964 0.0%   
Total assets Rs m4,156100,163 4.1%  
Interest coverage xNM44.7-  
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.11.0 116.1%   
Return on assets %-0.115.7 -0.8%  
Return on equity %-0.328.4 -1.0%  
Return on capital %034.3 0.0%  
Exports to sales %5.745.3 12.6%   
Imports to sales %6.55.9 108.9%   
Exports (fob) Rs m27044,537 0.6%   
Imports (cif) Rs m3065,838 5.2%   
Fx inflow Rs m37544,881 0.8%   
Fx outflow Rs m4709,069 5.2%   
Net fx Rs m-9635,812 -0.3%   
CASH FLOW
From Operations Rs m-819,938 -0.0%  
From Investments Rs m-146-9,039 1.6%  
From Financial Activity Rs m862-9,527 -9.1%  
Net Cashflow Rs m7091,372 51.6%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 15.7 5.9 266.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   12,856 44,069 29.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Pharma Stocks Witness Buying(01:30 pm)

After opening the day on a positive note, the Indian share markets have continued the momentum and are currently trading comfortably in green.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 21, 2017 01:29 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS